WO2009025168A1 - Liposome modifié par un sucre contenant un composé d'agent de contraste et un agent de contraste - Google Patents

Liposome modifié par un sucre contenant un composé d'agent de contraste et un agent de contraste Download PDF

Info

Publication number
WO2009025168A1
WO2009025168A1 PCT/JP2008/064014 JP2008064014W WO2009025168A1 WO 2009025168 A1 WO2009025168 A1 WO 2009025168A1 JP 2008064014 W JP2008064014 W JP 2008064014W WO 2009025168 A1 WO2009025168 A1 WO 2009025168A1
Authority
WO
WIPO (PCT)
Prior art keywords
contrast agent
sugar
containing compound
liposome containing
modified liposome
Prior art date
Application number
PCT/JP2008/064014
Other languages
English (en)
Japanese (ja)
Inventor
Yasuyuki Motokui
Norio Miura
Hidetaka Ninomiya
Takeshi Wada
Takamichi Murakami
Original Assignee
Konica Minolta Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Konica Minolta Holdings, Inc. filed Critical Konica Minolta Holdings, Inc.
Priority to JP2009528996A priority Critical patent/JP5370153B2/ja
Publication of WO2009025168A1 publication Critical patent/WO2009025168A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention vise à proposer un agent de contraste de radiographie, d'IRM et autres, particulièrement utile pour un diagnostic de cancer du foie. Dans ce but, l'invention fournit un liposome caractérisé en ce qu'il renferme un composé d'agent de contraste et comporte une surface modifiée par un sucre.
PCT/JP2008/064014 2007-08-20 2008-08-05 Liposome modifié par un sucre contenant un composé d'agent de contraste et un agent de contraste WO2009025168A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009528996A JP5370153B2 (ja) 2007-08-20 2008-08-05 造影剤用化合物含有糖修飾リポソーム及び造影剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-213598 2007-08-20
JP2007213598 2007-08-20

Publications (1)

Publication Number Publication Date
WO2009025168A1 true WO2009025168A1 (fr) 2009-02-26

Family

ID=40378076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/064014 WO2009025168A1 (fr) 2007-08-20 2008-08-05 Liposome modifié par un sucre contenant un composé d'agent de contraste et un agent de contraste

Country Status (2)

Country Link
JP (1) JP5370153B2 (fr)
WO (1) WO2009025168A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150024037A1 (en) * 2012-02-16 2015-01-22 The University Of Toledo Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06122634A (ja) * 1992-01-20 1994-05-06 Nippon Fine Chem Co Ltd リポソームを用いるガン診断薬およびガン治療薬
JPH07316079A (ja) * 1994-03-28 1995-12-05 Dai Ichi Seiyaku Co Ltd リポソーム
WO2007091661A1 (fr) * 2006-02-08 2007-08-16 National Institute Of Advanced Industrial Science And Technology Liposome modifié par une chaîne de sucre convenant pour l'imagerie moléculaire et utilisation et production de celui-ci
WO2008081686A1 (fr) * 2006-12-28 2008-07-10 Konica Minolta Holdings, Inc. Dérivé du cholestérol, liposomes, procédé d'obtention de liposomes et agent de contraste pour imagerie par rayons x

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2427601A (en) * 1999-11-30 2001-06-12 Arizona Board Of Regents On Behalf Of The University Of Arizona, The Radiation sensitive liposomes
JP2006069895A (ja) * 2004-08-31 2006-03-16 Fuji Photo Film Co Ltd トリヨードアリール基を有するアルキルアルコールのエステル化合物
JP2006193488A (ja) * 2005-01-14 2006-07-27 Kyoto Univ 免疫担当細胞指向型オリゴヌクレオチド・リポソーム複合体
JP2006298838A (ja) * 2005-04-21 2006-11-02 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤
JP2006298843A (ja) * 2005-04-21 2006-11-02 Konica Minolta Medical & Graphic Inc リポソームおよびリポソーム含有製剤の製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06122634A (ja) * 1992-01-20 1994-05-06 Nippon Fine Chem Co Ltd リポソームを用いるガン診断薬およびガン治療薬
JPH07316079A (ja) * 1994-03-28 1995-12-05 Dai Ichi Seiyaku Co Ltd リポソーム
WO2007091661A1 (fr) * 2006-02-08 2007-08-16 National Institute Of Advanced Industrial Science And Technology Liposome modifié par une chaîne de sucre convenant pour l'imagerie moléculaire et utilisation et production de celui-ci
WO2008081686A1 (fr) * 2006-12-28 2008-07-10 Konica Minolta Holdings, Inc. Dérivé du cholestérol, liposomes, procédé d'obtention de liposomes et agent de contraste pour imagerie par rayons x

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KATO E. ET AL.: "Synthesis and function of sialic acid-conjugated cholesterols as ganglioside analogs:their reconstitution to liposomes and interaction with rat lymphocytes.", PROCEEDINGS OF THE JAPAN ACADEMY,SERIES B, vol. 76, no. 5, 2000, pages 63 - 67 *
KAWAKAMI S. ET AL.: "Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1524, no. 2-3, 2000, pages 258 - 265 *
OKU N.: "Kinosei Liposomes no Kaihatsu to Iyaku eno Oyo. RES Kaihi Liposomes ni yoru Gan Shindan to Chiryo.", IGAKU NO AYUMI, vol. 178, no. 4, 1996, pages 236 - 237 *
TETSURO ARAKI ET AL.: "Liposomes-ka zoeizai ni yoru dobutsu model no kanzo shuyo zoei kenkyu", THE 67TH ANNUAL MEETING OF JAPAN RADIOLOGICAL SOCIETY SHOROKUSHU, 28 February 2008 (2008-02-28), pages S142 - S143 *
WITTENDORP-RECHENMANN E. ET AL.: "SUPERPARAMAGNETIC NANOPARTICLES CONTAINING LIPOSOMES AS POTENTIAL SPECIFIC CONTRAST AGENT FOR BRAIN MR IMAGING : INITIAL FEASIBILITY STUDY BY A COMBINED APPROACH WITH 59FE-ACTIVATED TRACK-AUTORADIOGRAPHY", JOURNAL OF TRACE AND MICROPROBE TECHNIQUES, vol. 16, no. 4, 1998, pages 523 - 534 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150024037A1 (en) * 2012-02-16 2015-01-22 The University Of Toledo Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making
AU2013221448B2 (en) * 2012-02-16 2017-02-23 The University Of Toledo Xenoantigen-displaying anti-cancer vaccines and method of making
US10206988B2 (en) 2012-02-16 2019-02-19 The University Of Toledo Xenoantigen-displaying anti-cancer vaccines and method of making

Also Published As

Publication number Publication date
JPWO2009025168A1 (ja) 2010-11-25
JP5370153B2 (ja) 2013-12-18

Similar Documents

Publication Publication Date Title
IL253885A0 (en) Ligands for cardiac innervation imaging
EP1797903A4 (fr) Agent de diagnostic pour tumeur
EP1779289A4 (fr) Systeme de diagnostic pour mammographie multimodale
EP1893245A4 (fr) Pegylation radiomarquee de ligands destines a etre utilises comme agents d'imagerie
WO2006106941A1 (fr) Tomodensitometre assiste par ordinateur
PL1720611T3 (pl) Marker diagnostyczny dla raka
HK1154052A1 (en) Kits for diagnosing prostate conditions
PL2272821T3 (pl) Trójpierścieniowe związki fenolowe
GB0716885D0 (en) Diagnostic agent
EP1848466A4 (fr) Agents de contraste irm pour diagnostic et pronostic de tumeurs
EP1991861A4 (fr) Tomographie par ordinateur à faisceau conique et à contraste de phase
IL211526A0 (en) Compounds and methods for 18f labeled agents, compositions comprising such compounds and their use for diagnostic imaging
EP2106451A4 (fr) Tests de diagnostic d'accompagnement pour un traitement du cancer
GB0611348D0 (en) Imaging system for locating retroreflectors
WO2009040742A9 (fr) Procédés pour une imagerie de la perfusion sanguine
EP2029771A4 (fr) Procédé diagnostique de la myopathie
EP1862804A4 (fr) Méthode pour diagnostiquer le cancer de la prostate
HRP20150472T1 (en) Imaging diagnostics by combining contrast agents
HK1134901A1 (en) Radioactive diagnostic imaging agent
BRPI0919551A2 (pt) agente e método de formação de imagem in vivo, composto precursor, kit, cassete, composição radiofarmacêutica, e, métodos para a preparação do agente de formação de imagem in vivo, e para diagnóstico de uma condição
EP2053968A4 (fr) Procédés d'imagerie du système lymphatique
WO2011146390A3 (fr) Compositions et procédés d'imagerie in vivo
EP2080526A4 (fr) Agent d'imagerie de diagnostic radioactif
WO2009025168A1 (fr) Liposome modifié par un sucre contenant un composé d'agent de contraste et un agent de contraste
EP1894577A4 (fr) Agent d'imagerie pour diagnostic radioactif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08792200

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2009528996

Country of ref document: JP

Kind code of ref document: A

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08792200

Country of ref document: EP

Kind code of ref document: A1